Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"What's New in Cutaneous Lupus Erythematosus: Guidelines, Biologics, and Beyond.","authors":"Beth A Childs, Joseph F Merola","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>We aim to review current treatment strategies for cutaneous lupus erythematosus (CLE) and highlight emerging therapies, evolving outcome measures, and practical considerations that may inform future management of this clinically heterogeneous disease.</p><p><strong>Methods: </strong>We conducted a narrative review of the literature using PubMed to identify relevant clinical trials, observational studies, and mechanistic investigations related to CLE treatment. Emphasis was placed on studies published within the past 15 years. Expert opinion from dermatology and rheumatology was incorporated to contextualize evolving therapies and their application in clinical practice.</p><p><strong>Results: </strong>Current management of CLE follows a stepwise framework, with antimalarials and immunosuppressants forming the foundation of systemic therapy. However, many patients experience refractory disease, especially in chronic or hypertrophic subtypes. Advances in the understanding of CLE pathogenesis have led to the development of targeted biologics and small molecule agents that modulate Type I interferon signaling, B- and T-cell activation, and inflammatory cytokine pathways. Novel tools such as Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI-A) and the Investigator Global Assessment for Cutaneous Lupus (CLA-IGA-R) are being validated to standardize disease assessment, while RNA tape sampling and real-world electronic health record (EHR)-based algorithms are enhancing research precision. Emerging therapies, such as belimumab, anifrolumab, litifilimab, deucravacitinib, and enpatoran, demonstrate promise in both clinical trials and real-world settings.</p><p><strong>Limitations: </strong>As a narrative review, this study is limited by the lack of systematic inclusion criteria and formal quality assessment of individual studies.</p><p><strong>Conclusion: </strong>Ongoing therapeutic innovation, guided by mechanistic insights and strengthened by the development of standardized outcome measures, is transforming the CLE landscape and advancing the goal of precision-based, durable disease control.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 1","pages":"17-26"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selected Abstracts from Elevate-Derm Fall Conference 2025.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 1-2 Suppl 1","pages":"S14-S31"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Enigma of Intramuscular Triamcinolone and Its Versatility as a Safe and Effective Dermatologic Therapy.","authors":"Douglas Robins, Vivek Vemugunta","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Intramuscular triamcinolone acetonide (IMT) has been used for the past 60 years, but a recent survey of 800 dermatologists showed that 55% use it rarely or not at all, primarily because of fear of adverse events. With a unique mechanism of action vs. other systemic corticosteroids, a relatively low dose, and short half-life, IMT can produce a long-term clinical anti-inflammtatory effect. This paper presents an argument for the efficacy of IMT with proper, safe use. In addition, this paper will discuss many of the clinical conditions for which IMT can be effective.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 1","pages":"47-49"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Use Recommendations and Stewardship Principles with Oral Antibiotics in Acne Vulgaris Management: An Expert Consensus Panel.","authors":"Angela L Rosenberg, Milaan Shah, James Q Del Rosso, Hilary Baldwin, Julie Harper, Adelaide A Hebert, Jonette Keri, Pearl Kwong, Evan Rieder, Linda Stein Gold, Brooke Bartley, Joshua Burshtein, Lauren DeBusk, Danny Zakria","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>The purpose of this meeting was for an expert panel to analyze current literature and provide updated consensus statements regarding the optimal management, safety, and efficacy of oral antibiotics in acne vulgaris (AV).</p><p><strong>Methods: </strong>A thorough literature search was conducted across PubMed, Scopus, and Google Scholar to identify English-language original research articles evaluating the use of oral antibiotics for AV. An expert panel of 8 dermatologists, specializing in the management of AV, convened to assess the findings and develop statements regarding oral antibiotics for AV. Each statement was approved through a modified Delphi process, and a strength of recommendation was assigned based on the Strength of Recommendation Taxonomy (SORT) criteria.</p><p><strong>Results: </strong>A total of 544 articles regarding the safety, efficacy, and management of oral antibiotics for AV were identified through the literature search. Following a rigorous screening process, 17 articles were deemed relevant to the research questions and provided to the panelists for review prior to the roundtable discussion. The panel reached unanimous agreement on 10 consensus statements and recommendations, assigning seven a strength of A, one a strength of B, and two a strength of C.</p><p><strong>Conclusion: </strong>The expert panel concluded that oral antibiotics can be used in the treatment of moderate-to-severe AV, oral antibiotics should be combined with topical treatments, and duration of use should be determined based on individualized patient care. Tetracyclines are recognized options for AV therapy, with sarecycline considered a preferred option for AV due to its targeted mode of action, unique ribosomal binding properties, narrow spectrum of antibiotic activity, lower bacterial resistance risk, and overall better tolerability. Additionally, tetracyclines should be avoided in pregnancy and in young children.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 12","pages":"21-29"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12867529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146120875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tattoo-related Uveitis: A Devastating and Fairly Common Association.","authors":"Mónica Navarrete-Martínez, Arturo Alejandro Macias-Rule, Michel Alexa Orozco-Brizuela, José Contreras-Ruiz","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 12","pages":"17-18"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12867526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146120874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Application of a Formulation Containing Hydroxypropyl Tetrahydropyrantriol and Niacinamide to Augment Anti-aging Benefits in a Double-blind, Randomized Nonablative Laser Treatment Study.","authors":"Glynis Ablon, Jyotsna Paturi, Franck Juchaux, Rebecca Barresi-Thornton, Benedicte Fallou, I-Chien Liao, Jinyuan Yan, Ying Chen, Julien Laboureau, Carine Ballihaut, Elena Catalan Martin, Jean-Thierry Simonnet, Xavier Marat, Qian Zheng","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>With advances in aesthetic procedures, best practices for postprocedure care to support immediate healing and augment efficacy are still without consensus. A postprocedure formula containing hydroxypropyl tetrahydropyrantriol (HPT) and niacinamide (NAM) has been developed. This study evaluated the functional benefits and clinical efficacy of pairing HPT/NAM formula with nonablative fractional laser treatment.</p><p><strong>Methods: </strong>The functional benefits of HPT/NAM were explored using 2D cellular models, reconstructed skin equivalents, and ex vivo skin models. The clinical efficacy of a HPT/NAM formula vs. a clinical control (Aquaphor Healing Ointment) was investigated through a randomized, double-blind, split-face, multicenter, multiethnic study with a White and a Northeast Asian panel. The investigative products were randomly assigned to one side of the face following a single full-face fractional nonablative laser procedure, and the products were applied twice daily for 56 days.</p><p><strong>Results: </strong>In vitro testing showed that the HPT/NAM combination decreased the secretion of prostaglandin E2 (PGE2), encouraged the production of glycosaminoglycan, α-smooth muscle actin, and various angiogenic growth factors. In both panels, the HPT/NAM formula demonstrated significant improvement vs. the clinical control for key anti-aging parameters such as fine lines, crow's feet wrinkles, skin roughness, and overall healthy appearance over the course of 56 days.</p><p><strong>Limitations: </strong>This study only investigated the pairing of HPT/NAM formula with nonablative laser treatment.</p><p><strong>Conclusion: </strong>This study demonstrated comparable healing benefits to the clinical control along with augmented skin resurfacing benefits with HPT/NAM use following a nonablative fractional laser treatment.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 12","pages":"66-72"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12871497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laser Hair Reduction to the Residuum Improves Quality of Life in People with Amputations.","authors":"Sophie Diong, Catriona Gallagher, Julianne Clowry, Alan D Irvine, Maeve A McAleer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>People with amputations using limb prosthetics commonly develop dermatologic complications, such as impaired skin integrity and folliculitis, at the residuum-prosthesis interface (RPI). Dermatologic complications are the primary cause of dissatisfaction with prosthetics, hindering rehabilitation and leading to prosthesis abandonment. This has a deleterious impact on health-related quality of life (HRQOL). Positive outcomes have been associated with laser hair reduction (LHR) for those with traumatic lower limb amputations; however, this has not been studied in those with upper limb amputations or amputations due to other conditions. We performed a prospective study to assess the effects of skin conditions at the RPI on HRQOL and determine the potential benefit from LHR. Four patients were identified: 75% (n=3) with lower-limb amputations and 25% (n=1) with upper limb amputations. Amputation indications included infection (25%, n=1), congenital malformations (25%, n=1) and trauma (50%, n=2). Participants received 6 sessions of LHR, either alexandrite 755nm alone or in combination with Nd:YAG 1064nm laser. The Skindex-16 survey was performed along with 7 amputee-specific questions. Improvements in HRQOL were seen in all patients and subscales, with an overall average improvement of 50%. Functioning subscale improvement was greatest, at 60%. All patients (100%) were satisfied with LHR treatment. To our knowledge, this is the first study to examine the impact of LHR on the HRQOL of people with upper and lower limb prostheses. LHR is a minimally invasive technique to treat and prevent common dermatologic complications of the RPI, promoting improved self-confidence and prosthesis fit. This study identified an important role for dermatologists to engage with this community to improve their functional capacity and quality of life.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 12","pages":"42-44"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12867527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146120905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology.","authors":"Courtney A Chau, Hilary E Baldwin, James Q Del Rosso, Julie C Harper, Edward Lain, Todd Schlesinger, Ali Shahbaz, Heather Woolery-Lloyd, Jennifer C Jaworski, Melissa S Seal, Diane Hanna, Peter Lio","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Many inflammatory skin conditions share mechanistic pathways involving multiple receptors and cytokines. Perhaps there is no better endorsement of this idea than the foundational concept of \"steroid-responsive dermatoses.\" Similarly, targeting the phosphodiesterase 4 (PDE4) enzyme, which exists at the crux of several pathways that contribute to inflammatory skin diseases, offers an avenue by which the pathogenesis of multiple conditions may be interrupted. This suggests that PDE4 inhibitors may assume a similar complementary framework for treating \"PDE4 inhibitor-responsive dermatoses.\" Certain formulations of PDE4 inhibitors (including apremilast, crisaborole, and roflumilast) have undergone rigorous investigation in clinical trials and demonstrated robust efficacy and safety in many dermatologic conditions, achieving United States Food and Drug Administration approval for atopic dermatitis, psoriasis, and seborrheic dermatitis. Herein, we summarize the clinical evidence supporting the emerging concept of \"PDE4 inhibitor-responsive dermatoses\" and propose that PDE4 inhibition offers an additional pathway to achieving desired clinical outcomes.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 12","pages":"50-65"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12871500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laser-assisted Analgesic and Vasoconstrictive Drug Delivery During and After Fractional CO₂ Resurfacing: A Novel Technique to Enhance Procedural Tolerance and Recovery.","authors":"Iman Ali, Roger Ceilley, Ciaran Smythe","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Fractional carbon dioxide (CO₂) laser resurfacing is an effective treatment of various dermatological conditions. Pain, erythema, and edema following fractional ablative resurfacing are key limitations to patient comfort and satisfaction.</p><p><strong>Objective: </strong>This study aims to describe a novel technique using laser-assisted drug delivery to administer a combination of local anesthetics and epinephrine both during and after fractional CO₂ laser resurfacing, enhancing procedural anesthesia and postprocedure recovery.</p><p><strong>Methods: </strong>We performed an observational review of patient-reported pain scores and clinical outcomes in patients treated with application of an anesthetic spray during and after fractional CO₂ laser resurfacing treatments.</p><p><strong>Results: </strong>Patients demonstrated an average of 68% reduction in pain scores (<i>p</i><0.001) scores postapplication, with additional clinical improvements in postlaser erythema and edema.</p><p><strong>Conclusion: </strong>Laser-assisted drug delivery of local anesthetics and epinephrine after fractional ablative resurfacing appears to offer a simple, low-cost adjunct for improving patient experience and recovery. Further investigation is warranted.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 12","pages":"73-75"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12871495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durability of Conventional Immunosuppressants in the Treatment of Oral Lichen Planus.","authors":"Rachel M Seifert, Christiaan H Noot, Naiem T Issa, Christopher M Hull, Jamie L W Rhoads, Jennie T Clarke, Christopher B Hansen, John J Zone, Zachary H Hopkins","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Oral lichen planus (OLP) is an inflammatory disease involving the oral mucosa. It affects roughly 0.5% to 2% of the global population and has an associated risk of oral squamous cell carcinoma. Treatment of moderate to severe OLP often requires immunosuppression. The durability of immunosuppressive medication is currently unknown and is important for understanding therapeutic testing needs.</p><p><strong>Objective: </strong>We investigated traditional immunosuppressive drug survival in patients with OLP and evaluated potential discontinuation factors.</p><p><strong>Methods: </strong>We retrospectively analyzed patients with OLP treated with methotrexate, mycophenolate, azathioprine, or cyclosporine. Time to medication discontinuation was evaluated using the Kaplan-Meier estimator, and Cox proportional hazards regression was used to compare the risk of discontinuing a medication between medications and across patient demographic and disease factors.</p><p><strong>Results: </strong>We identified 125 treatment periods with mycophenolate (n=58), methotrexate (n=34), azathioprine (n=19), or cyclosporine (n=14). Most patients had erosive disease (92%), and median time (IQR) to discontinuation due to adverse events or inefficacy was 9.43 months (6.51-16.1). Overall, only cyclosporine was associated with higher risk of discontinuation compared to methotrexate (hazard ratio [HR]: 2.94; 95% confidence interval [CI]: 1.32-6.45). There was no evidence for risk differences across age or sex for the overall cohort. Within individual medication groups, age was associated with a small increased risk of discontinuing mycophenolate (HR: 1.05; 95% CI: 1.00-1.10) and a small decreased risk in cyclosporine (HR=0.94, 95% CI: 0.89-0.99). Otherwise, no demographic factors were associated with discontinuation. Treatment success was reported 8 times.</p><p><strong>Discussion: </strong>Immunosuppressive medications were frequently discontinued after short time periods, and few were discontinued due to success. These data highlight the need for better systemic therapy in OLP.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 12","pages":"45-49"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12871496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}